Literature DB >> 1550111

Increased expression of natural-killer-associated and activation antigens in multiple myeloma.

M Gonzalez1, J F San Miguel, A Gascon, M J Moro, J M Hernandez, F Ortega, R Jimenez, L Guerras, M Romero, F Casanova.   

Abstract

The expression of both natural-killer (NK)-associated and activation antigens was studied by flow cytometry in the peripheral blood of 47 untreated multiple myeloma (MM) patients. A significant increase in both absolute and relative numbers of CD57 positive cells as well as in the proportion of CD16 and CD11b cells was observed in patients with MM, specially in those in early stages of the disease (clinical stages I and II), suggesting a possible surveillance mechanism in response to an emerging malignant clone. Additional double stainings showed that strong CD16+ NK cells coexpress the CD56, CD11b, and CD2 antigens, while they lacked CD3, CD5, and WT31 antigens. Moreover, the previously reported increase in CD8 cells present in MM would be mainly due to a subset of CD8 cells that coexpress the CD57 Ags. The expression of activation antigens, especially CD38, was increased in peripheral blood lymphocytes of MM patients, the differences reaching statistical significance both in absolute and relative numbers in those cases with high numbers of CD16 NK cells and thus suggesting that these cells are functionally activated. These results reveal the existence of an increase in NK and activated cells in the peripheral blood of myeloma patients that may reflect a host's immunological mechanism in an attempt to modulate tumor cell growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550111     DOI: 10.1002/ajh.2830390203

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors:  Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal:  Clin Cancer Res       Date:  2015-05-21       Impact factor: 12.531

2.  Immunological features of sporadic multinodular goiter.

Authors:  J J Corrales; A Orfao; J M Miralles; M C López-Berges; L C García; M González; M T Mories; J San Miguel
Journal:  Clin Investig       Date:  1993-07

3.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Authors:  Don M Benson; Courtney E Bakan; Anjali Mishra; Craig C Hofmeister; Yvonne Efebera; Brian Becknell; Robert A Baiocchi; Jianying Zhang; Jianhua Yu; Megan K Smith; Carli N Greenfield; Pierluigi Porcu; Steven M Devine; Rinat Rotem-Yehudar; Gerard Lozanski; John C Byrd; Michael A Caligiuri
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

4.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Authors:  Don M Benson; Craig C Hofmeister; Swaminathan Padmanabhan; Attaya Suvannasankha; Sundar Jagannath; Rafat Abonour; Courtney Bakan; Pascale Andre; Yvonne Efebera; Jérôme Tiollier; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

5.  Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

Authors:  M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 6.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

7.  Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Miguel-Garcia; E Matutes; F Tarin; J Garcia-Talavera; A Miguel-Sosa; F Carbonell; D Catovsky
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

Review 8.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

9.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

Review 10.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.